Going northbound bound in big way22 Apr 2026 14:19
If they get this $15 mill funding given that company is only worth £20mill what would this one piece of news alone do to the share price.
Then Ask yourself how would the appetite stateside be for investors to pile in.
They won't be paying anything as low as today's prices.
Then there is everything else the company has going on.
RNs 3rd
If the efficacy studies are successful, Solvonis would be well positioned to compete for a non-dilutive NIH research grant, which can provide up to US$3 million per year for as long as five years. These grants are competitive, but completion of early preclinical studies would provide the type of safety and efficacy data needed to support Solvonis' grant application. This creates a potential pathway from funded NIDA preclinical work through to potential NIH-funded clinical trials in humans.